{"disease":{"id":"severe-asthma","name":"severe asthma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"amg-157","indication_name":"Severe asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tezspire","generic_name":"AMG 157","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Thymic stromal lymphopoietin","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":66,"revenue":"800","mechanism":"Tezspire blocks the action of Thymic Stromal Lymphopoietin (TSLP), a protein that triggers inflammation in the airways."},{"drug_id":"tezepelumab","indication_name":"Severe Asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tezspire","generic_name":"TEZEPELUMAB","company_name":"AstraZeneca / Amgen","drug_phase":"marketed","molecular_target":"","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"depemokimab","indication_name":"severe asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exdensur","generic_name":"DEPEMOKIMAB","company_name":"Glaxosmithkline Llc","drug_phase":"marketed","molecular_target":"Histamine","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Exdensur works by binding to histamine, preventing it from interacting with its receptors and reducing inflammation and airway constriction."},{"drug_id":"tezepelumab-ekko","indication_name":"Severe asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TEZSPIRE","generic_name":"TEZEPELUMAB-EKKO","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Thymic stromal lymphopoietin","drug_class":"Thymic Stromal Lymphopoietin Blocker [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"tezspire","indication_name":"Severe asthma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tezspire","company_name":"Qilu Pharmaceutical Co., Ltd.","drug_phase":"marketed","molecular_target":"Thymic stromal lymphopoietin","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03608566","title":"Russian Severe Asthma Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":7000,"lead_sponsor_name":"Interregional Public Organization, Russian Respiratory Society","has_results":false},{"nct_id":"NCT06472310","title":"Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06625216","title":"Severe Asthma Network Italy","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Società Italiana di Allergologia, Asma e Immunologia Clinica","has_results":false},{"nct_id":"NCT06035289","title":"Register Schweres Asthma - German Asthma Net e.V.","phase":"","overall_status":"RECRUITING","enrollment_count":4500,"lead_sponsor_name":"German Asthma Net e.V.","has_results":false},{"nct_id":"NCT07241117","title":"CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03629782","title":"Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":1032,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03931954","title":"Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":794,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04045587","title":"International Severe Asthma Registry: Canadian Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT06024902","title":"Clinical Characteristics of Severe Childhood Asthma","phase":"","overall_status":"COMPLETED","enrollment_count":650,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT03984253","title":"Swiss Severe Asthma Register","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Prof. Dr. Jörg Leuppi","has_results":false},{"nct_id":"NCT07532265","title":"A Phase 2 Dose Ranging Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":512,"lead_sponsor_name":"Kinaset Therapeutics Inc","has_results":false},{"nct_id":"NCT06465485","title":"STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":504,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06422663","title":"A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06196879","title":"A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":479,"lead_sponsor_name":"Upstream Bio Inc.","has_results":false},{"nct_id":"NCT05729711","title":"TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":416,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03925415","title":"BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)","phase":"","overall_status":"COMPLETED","enrollment_count":414,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04031261","title":"National Validation and Sensitivity to Change of the SAQ","phase":"","overall_status":"COMPLETED","enrollment_count":410,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT07363642","title":"Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06903780","title":"Experience of Biologic Treatments for Severe Asthma: a Survey","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Royal Devon and Exeter NHS Foundation Trust","has_results":false},{"nct_id":"NCT04438408","title":"National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06455462","title":"Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres","phase":"","overall_status":"COMPLETED","enrollment_count":352,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07214753","title":"A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy","phase":"","overall_status":"RECRUITING","enrollment_count":335,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06473779","title":"Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":326,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04773678","title":"Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":322,"lead_sponsor_name":"Connect Biopharm LLC","has_results":false},{"nct_id":"NCT02717689","title":"A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma","phase":"NA","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Belfast Health and Social Care Trust","has_results":false},{"nct_id":"NCT06348407","title":"A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05603845","title":"Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":291,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01350336","title":"Bronchial Thermoplasty in Severe Persistent Asthma","phase":"NA","overall_status":"COMPLETED","enrollment_count":284,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT05180357","title":"RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.","phase":"","overall_status":"COMPLETED","enrollment_count":273,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03387722","title":"Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study","phase":"","overall_status":"COMPLETED","enrollment_count":253,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05851443","title":"A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT07328035","title":"Remission in Adults With Severe Asthma in Thailand","phase":"","overall_status":"RECRUITING","enrollment_count":230,"lead_sponsor_name":"Thammasat University","has_results":false},{"nct_id":"NCT07372287","title":"A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":230,"lead_sponsor_name":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04648839","title":"Observational Retrospective Study on Clinical Outcomes of Patients Receiving Benralizumab in Spain.","phase":"","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04272463","title":"ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab","phase":"","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06998095","title":"Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":210,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05576454","title":"Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":207,"lead_sponsor_name":"Bio-Thera Solutions","has_results":false},{"nct_id":"NCT05472324","title":"Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06818019","title":"Withdrawal of Dupilumab in Severe Asthma","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":205,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT06283290","title":"PROPE Severe Asthma Study in Egypt","phase":"","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06421402","title":"K-HEALTH in AIR - Barcelona Pilot - Cohort","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Institut d'Investigacions Biomèdiques August Pi i Sunyer","has_results":false},{"nct_id":"NCT05164939","title":"Precision Medicine Intervention in Severe Asthma (PRISM) Study","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT07218172","title":"Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)","phase":"","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07403487","title":"Phase II Trial of RC1416 Injection in Asthma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":195,"lead_sponsor_name":"Nanjing RegeneCore Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT03833141","title":"Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.","phase":"","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04159519","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":170,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05440656","title":"A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.","phase":"","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01862289","title":"Prevalence of Hyperventilation Syndrome in Difficult Asthma","phase":"NA","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06666504","title":"The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The TezEx Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT05384938","title":"FAsenra Safety Trial in India","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":139,"lead_sponsor_name":"AstraZeneca","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}